Neuromedin U (NMU)

Neuromedin U is a highly conserved neuropeptide broadly distributed in mammals, with particularly high expression in the gastrointestinal tract, pituitary, and specific CNS regions such as the hypothalamus and spinal cord[1][2][3]. It exerts its biological effects primarily via two G protein-coupled receptors, NMUR1 and NMUR2, with NMUR1 more prominent in peripheral tissues and NMUR2 in the CNS[1][4][5]. NMU regulates a wide variety of physiological processes, including smooth muscle contraction, appetite, blood pressure, stress response, pain perception, and bone growth. Its knockout or functional deficiency is linked to obesity in animal models and certain human polymorphisms, and altered NMU signaling has been implicated in cancer, metabolic syndrome, and inflammatory disorders[2][3][4]. NMU’s effects via its receptors are mediated through intracellular calcium signaling and various second messengers. The peptide is processed from a larger precursor protein (prepro-NMU), yielding active peptides including NMU-25 and precursor-related peptides (NURP33 and NURP36)[4]. The diversity and physiological breadth of NMU’s actions make it a potential but challenging therapeutic target[1][3][5].

Other names

Neuromedin-UNeuromedin U precursor-related peptide 36Neuromedin U precursor-related peptide 33Neuromedin-U-25NURP36NURP33NmU-25prepro-NMUneuromedin U preproproteinneuromedin S (related peptide)

Drugs or experimental agonists/antagonists for NMU act by agonizing or antagonizing NMUR1 (peripheral, especially gastrointestinal) or NMUR2 (central, nervous system), altering intracellular calcium mobilization and distinct downstream pathways (e.g., MAPK/ERK, inhibition of cAMP production)[1][3][5].